Parvinderjit Khanuja, MD
Hematology & Oncology · Chandler, AZNPI 1053385765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,290 of the $11,895 with a category attached, or 69.7%. It is spread thinly across 57 manufacturers, the largest accounting for just 19.7%. Reporting peaked in 2019 at $3,928 and has fallen 74.4% since, to $1,006 in 2025.
Across 383 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mckesson Specialty Care Distribution, LLC$2K
- US Oncology Corporate, Inc.$2K
- Genentech USA, Inc.$656
- Pfizer$637
- Bristol Myers Squibb$554
- AbbVie$552
- plus $6K from 51 others
What the payments were for
- Consulting fees$2,34520%
- Travel & lodging$9818%
- Food & beverage$8,29070%
- Education$2592%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,895 in reported general payments places this provider in the 60th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 12 | $167,588 |
| Imatinib Mesylate | 15 | $1,122 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chandler
- Sujith KalmadiChandler$1.4M
- Mikhail ShtivelbandChandler$42K
- Rohit SudChandler$34K
- Arun SingaviChandler$26K
- Karen Ortiz CruzChandler$26K
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Sumit MadanGilbert$422K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.